Multitude Therapeutics, a strategic partner of AsymBio, announced National Medical Products Administration (NMPA) has accepted the company’s IND application for AMT-676, an anti-CDH17 antibody-drug conjugate (ADC). AsymBio, the leading CDMO solutions provider, warmly extends congratulations on this major milestone achievement.
With this IND approval, Multitude Therapeutics will be able to conduct phase 1 clinical trials in China for patients with advanced solid tumors, which will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMT-676.
We look forward to continuing our collaboration to advance their clinical trials to solve unmet medical needs for patients worldwide.